Ark Make investments analyst breaks down Adaptive Biotechnologies and Invitae

Chad Robins, CEO of Adaptive Biotechnologies. Anjali Sundaram | CNBC Ark Make investments analyst Simon Barnett on Monday defined the agency’s method to what it calls the genomic revolution, breaking down two of its favourite holdings: Adaptive Biotechnologies and Invitae. In an interview on CNBC’s “Closing Bell,” Barnett stated the Cathie Wooden-led Ark Make investments


Chad Robins, CEO of Adaptive Biotechnologies.

Anjali Sundaram | CNBC

Ark Make investments analyst Simon Barnett on Monday defined the agency’s method to what it calls the genomic revolution, breaking down two of its favourite holdings: Adaptive Biotechnologies and Invitae.

In an interview on CNBC’s “Closing Bell,” Barnett stated the Cathie Wooden-led Ark Make investments sees main potential for buyers within the department of molecular biology often known as genomics, calling it “one of the transformative funding alternatives of the century.”

Ark’s household of funds contains the Genomic Revolution ETF (ARKG), which seeks to supply buyers publicity to areas resembling DNA sequencing expertise and molecular diagnostics.

ARKG is down about 7% yr so far.

Nonetheless, previously 12 months, the ETF has risen roughly 160%. The agency’s flagship fund is the Ark Innovation ETF (ARKK), which has fallen about 1.6% to this point in 2021. ARKK is also up almost 160% previously 12 months.



Supply hyperlink

The Fund Times
ADMINISTRATOR
PROFILE

Posts Carousel

Leave a Comment

Your email address will not be published. Required fields are marked with *

Latest Posts

Top Authors

Most Commented

Featured Videos